EFG International AG Takes Position in Scholar Rock Holding Corporation $SRRK

EFG International AG acquired a new position in Scholar Rock Holding Corporation (NASDAQ:SRRK) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 110,634 shares of the company’s stock, valued at approximately $6,082,000. EFG International AG owned 0.09% of Scholar Rock at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in SRRK. Jennison Associates LLC increased its holdings in shares of Scholar Rock by 74.0% in the 4th quarter. Jennison Associates LLC now owns 2,795,188 shares of the company’s stock valued at $123,128,000 after acquiring an additional 1,188,676 shares during the period. Nicholas Investment Partners LP bought a new position in shares of Scholar Rock during the 2nd quarter worth approximately $4,968,000. iA Global Asset Management Inc. bought a new position in shares of Scholar Rock during the 4th quarter worth approximately $5,430,000. Geode Capital Management LLC lifted its position in Scholar Rock by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 2,034,024 shares of the company’s stock valued at $89,616,000 after acquiring an additional 79,214 shares during the last quarter. Finally, Norges Bank purchased a new stake in Scholar Rock during the fourth quarter valued at approximately $91,603,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Stock Up 0.1%

SRRK stock opened at $58.25 on Wednesday. The stock has a market capitalization of $7.09 billion, a PE ratio of -16.88 and a beta of 0.69. Scholar Rock Holding Corporation has a 52 week low of $27.07 and a 52 week high of $59.48. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The firm has a 50 day moving average of $52.36 and a 200 day moving average of $48.64.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.84). During the same quarter last year, the business posted ($0.98) EPS. Sell-side analysts forecast that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current year.

Insider Activity

In other Scholar Rock news, Director Joshua Reed sold 3,053 shares of Scholar Rock stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the completion of the sale, the director owned 19,518 shares of the company’s stock, valued at approximately $1,048,897.32. The trade was a 13.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey S. Flier sold 3,053 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total value of $164,495.64. Following the sale, the director owned 27,856 shares in the company, valued at approximately $1,500,881.28. The trade was a 9.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 17,149 shares of company stock valued at $923,108. 10.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

SRRK has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a report on Thursday, June 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Friday, July 17th. Barclays raised their price objective on Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Citigroup boosted their target price on Scholar Rock from $58.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $76.00 target price on shares of Scholar Rock in a research report on Friday, August 7th. Four research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Scholar Rock has an average rating of “Buy” and a consensus price target of $58.77.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).